Hepatitis B virus replicates a DNA genome through reverse transcription of a pregenomic RNA (pgRNA) by using a multifunctional polymerase (HP). A critical function of HP is its specific association with a viral RNA signal, termed (H), located on pgRNA, which is required for specific packaging of pgRNA into viral nucleocapsids and initiation of viral reverse transcription. HP initiates reverse transcription by using itself as a protein primer (protein priming) and H as the obligatory template. HP is made up of four domains, including the terminal protein (TP), the spacer, the reverse transcriptase (RT), and the RNase H domains. A recently developed, H-dependent, in vitro protein priming assay was used in this study to demonstrate that almost the entire TP and RT domains and most of the RNase H domain were required for protein priming. Specific residues within TP, RT, and the spacer were identified as being critical for HP-H binding and/or protein priming. Comparison of HP sequence requirements for H binding, pgRNA packaging, and protein priming allowed the classification of the HP mutants into five groups, each with distinct effects on these complex and related processes. Detailed characterization of HP requirements for these related and essential functions of HP will further elucidate the mechanisms of its multiple functions and aid in the targeting of these functions for antiviral therapy.
H
epatitis B virus (HBV), a member of the Hepadnaviridae family, chronically infects over 350 million people worldwide and causes a million mortalities per year due to hepatic failure, cirrhosis, and hepatocellular carcinoma (1) . HBV encodes a multifunctional polymerase (HP), a specialized reverse transcriptase (RT) which replicates the viral 3.2-kb, partially double-stranded DNA genome via an RNA intermediate termed pregenomic RNA (pgRNA) (2) (3) (4) . HP is composed of four domains, including, from the N terminus to the C terminus, the terminal protein (TP), the spacer that is nonessential for HP functions, the RT, and the RNase H domains ( Fig. 1) (3, (5) (6) (7) . The RT domain of HP, with its YMDD active site, and the RNase H domain, with its D-E-D-D motif, are homologous to the retroviral counterparts, while TP is unique to hepadnaviruses (6) (7) (8) (9) .
Both the initiation of viral reverse transcription and the assembly of replication-competent nucleocapsids in HBV depend critically on the specific interaction between HP and pgRNA via an RNA element, termed epsilon (Hε), near the 5= end of pgRNA in a host chaperone-dependent process (10) (11) (12) (13) (14) (15) (16) . Thus, HP-Hε binding is required for packaging of both HP and pgRNA into nucleocapsids, where viral DNA synthesis occurs (17) (18) (19) (20) (21) . Furthermore, the HP-Hε interaction also triggers initiation of viral reverse transcription in a process termed protein priming, which occurs independently of nucleocapsids (22) (23) (24) (25) (26) (27) (28) (29) (30) . In protein priming, HP functions both as a protein primer, with the hydroxyl group of a specific tyrosine residue (Y63) on its TP domain used to initiate viral DNA synthesis, as well as the catalyst, with the RT active site being required to form a phosphotyrosyl linkage between Y63 and the first nucleotide residue of the viral minus-strand DNA. Hε also serves two essential roles during protein priming, acting as the obligatory template for viral DNA synthesis and also as an activator of HP catalytic activity.
Analyses of the structural requirements of both HP and Hε for HP-Hε interactions have revealed the sequences of both HP and Hε to be required for this process (13, 14, 26) . Minimum requirements of HP for binding Hε include the central region of TP and the N-terminal region of RT, while the RNase H domain is completely dispensable. Hε, which features a conserved lower stem, an internal bulge, an upper stem, and an apical loop, requires only its central portion adjacent to and including the internal bulge for HP binding, while its apical loop is entirely dispensable (13, 26, (31) (32) (33) (34) (35) . While the HP-Hε interaction is required for packaging of HP and pgRNA into nucleocapsids, pgRNA packaging has additional requirements beyond HP-Hε binding. In particular, pgRNA packaging appears to require the entire length of HP and all the structural elements of Hε plus a closely spaced 5= cap (26, 36) . Biochemical and genetic studies to identify HP sequences required for protein priming have been limited, until very recently, by the lack of in vitro assays that faithfully recapitulate HP protein priming under cell-free conditions. By employing HP expressed in insect cells, which displays Hε-independent protein priming activity in vitro, it was shown that the YMDD active-site motif in RT and Y63 in TP are both required for protein priming in this system, as are TP, RT, and most of the RNase H domain (27, (37) (38) (39) . However, this Hε-independent priming activity may represent the template-independent, protein-primed terminal transferase activity of HP that we discovered recently (28) and may not faithfully recapitulate the HP requirements for Hε-dependent protein priming. Genetic studies in cell culture have identified residues within TP and RT that are required for viral replication, although their specific roles in Hε binding and protein priming remain to be defined. R105 and Y173 in TP are both important for RNA packaging (40) , and W74 and Y147 in TP are important for viral DNA synthesis but not pgRNA packaging (41) . Three cysteine residues near the C terminus of the spacer and one at the N terminus of RT are also critical for RNA packaging (42) . In addition, the polymerase from the related duck HBV (DHBV) has been used extensively as a model system for HP. The DHBV polymerase (DP) requires the central portion of TP and the N-terminal part of RT for DP-DHBV ε (Dε) binding and protein priming, with the remaining sequences, including the entire RNase H domain, being dispensable (12, 43, 44) . Further analysis of DP led to the identification of the T3 and RT1 motifs in TP and RT, respectively, which are highly conserved between DP and HP and are critical for DP-Dε binding and protein priming (Fig. 1) (45, 46) .
We recently developed an Hε-dependent, HP in vitro priming system using HP purified from human cells as a priming-active HP-Hε complex (26) . Using this system, we demonstrated that the Hε requirements to support HP protein priming are remarkably similar to those for pgRNA packaging (26) . This same system allows the simultaneous measurement of HP-Hε binding in living cells (26) . The exact same HP proteins used in the HP-Hε binding and protein priming reactions can also be used in trans-complementation assays to determine their ability to support pgRNA packaging in the same host cells as those used for the other assays. These systems therefore afford the opportunity to carry out comparative analysis of HP and Hε requirements for protein-RNA interactions, pgRNA packaging, and protein priming, all in the same host cells and using the same HP and Hε constructs. Taking advantage of these systems, we have characterized two major groups of HP mutants for their effects on HP-Hε binding and protein priming. The first set of mutants included single-and multiple-residue substitutions in TP and RT, both within and outside the T3 and RT1 motifs, which are known to affect HP activities and HBV replication. The second set of mutants included extensive domain truncations in HP in an attempt to map the domain boundaries of HP for protein priming. Furthermore, Hε binding and pgRNA packaging activities of selected HP mutants were also determined by using the same HP expression system to allow direct comparison of the HP requirements for all three re- Positions of previously identified residues and motifs important for HP function are highlighted. (B) The amino acid residues of the T3 and RT1 motifs are denoted, along with the mutations within these motifs used in this study. T3 and RT1 HP mutants were analyzed for RNA packaging in a previous study but were named differently because of the use of HP in the adw2 strain (48) , which differs slightly in amino acid sequence from the HP in the ayw strain used in this study. For ease of comparison, the mutant names used in this study are shown with the alternate names, in parentheses, used in that study: K153A/A154G (HT3 155/156), G155A/I156A (HT3 157/158), K159A/R160A (HT3 161/162), V365A/D366A (HRT1 378 -379), N371A/T372A (HRT1 384 -385), A373G/E374A (HRT1 386 -387), and R386A/G387A (HRT1 399 -400). The cysteine mutants were originally named C135A, C146A, C150A (within the spacer), and RTC06A (within RT) (42) but are designated in this study according to their positions in the context of full-length HP. (C) All mutant HP proteins were expressed and purified with Hε (lanes 3 to 8, 10, 13 to 16, and 19 to 22), while WT HP was expressed with (lanes 2, 9, 12, and 18) or without (lanes 1, 11, and 17) Hε. WT and mutant HPs were resolved by SDS-PAGE and detected by Western blot analysis using the anti-Flag antibody. Full-length HP and the 76-kDa protein molecular mass marker are indicated. lated HP functions, namely, Hε binding, pgRNA packaging, and protein priming.
MATERIALS AND METHODS
Plasmids. Wild-type (WT) HP was expressed by using pcDNA-3FHP, which encodes an N-terminally 3ϫFlag-tagged HP gene (strain ayw) under the cytomegalovirus (CMV) promoter, while Hε was coexpressed by using pCMV-HE, as previously described (26, 28, 47) . For the evaluation of HBV T3 and RT1 motifs for their contribution to in vivo RNA binding, paired alanine-scanning mutations within the HP T3 and RT1 motifs (48) were transferred to pcDNA-3FHP. Plasmids for expressing point mutations affecting selected hydrophobic and charged residues in TP outside the T3 motif and the four cysteines in the spacer and RT along with the corresponding WT HP (40) (41) (42) were kindly provided by Wang-Shick Ryu. These constructs are in a different vector background from those used to express the T3 and RT1 mutants and contain additional HBV sequences downstream of the HP coding sequence such that the HP mRNAs produced contain a 3= copy of Hε after the HP coding sequence. PCR-mediated mutagenesis was used to produce N-terminal, C-terminal, and internal HP deletions in the pcDNA-3FHP background.
Protein expression and purification, in vivo H binding, and RNA packaging. WT and mutant HP proteins were expressed in HEK293T cells, with or without coexpression of the Hε RNA, and purified by using protein A/G beads coupled to anti-Flag antibody, as previously described (26) . Approximately 2 g HP and 3 ng Hε were expressed per 10-cm dish of transfected cells (26) . RNA was extracted from purified HP proteins or cytoplasmic lysates and detected by Northern blot analysis following resolution by urea-polyacrylamide gel electrophoresis (PAGE), as previously described (26) . The RNA packaging assay was also conducted by using transiently transfected HEK293T cells, as previously outlined (26), using pCMVHBV-Pol Ϫ to express pgRNA and all viral proteins except HP and the HP expression plasmids to provide HP in trans.
In vitro protein priming assay. WT HP and HP mutants were analyzed for their protein priming activities in vitro as previously described (26, 28, 47) , with minor modifications. Flag lysis buffer from HP purification was removed from aliquots of HP-bound anti-Flag affinity beads. TMgNK buffer (20 mM Tris-HCl [pH 7.0], 15 mM NaCl, 10 mM KCl, 4 mM MgCl 2 ) with 1ϫ EDTA-free protease inhibitor cocktail (Roche), 4 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1 unit RNasin Plus RNase inhibitor (Promega) per l buffer was added to the beads. One microliter of [␣-32 P]dGTP (10 mCi/ml and 3,000 Ci/mmol; PerkinElmer) was then added, and the reaction mixtures were incubated at 25°C for 4 h with shaking. Alternatively, protein priming was performed in TMnNK buffer (same as TMgNK buffer except containing 2 mM MnCl 2 instead of MgCl 2 ). The beads were then washed in TNK buffer (20 mM Tris-HCl [pH 7.0], 15 mM NaCl, 10 mM KCl) plus protease inhibitors (28 M E-64, 1 mM PMSF, 5 g/ml leupeptin) and 10 mM ␤-mercaptoethanol. The washed beads were then boiled in 2ϫ sodium dodecyl sulfate (SDS) sample buffer for 10 min to elute the bound proteins. Radiolabeled HP as a result of protein priming was resolved by running the eluate on an SDS-12.5% polyacrylamide gel and detected by autoradiography.
RESULTS
Expression and purification of HP substitution mutants. We selected four groups of single-and double-substitution HP mutants for analysis based on their phenotypes in previous studies: (i) T3 motif mutants, (ii) RT1 motif mutants, (iii) mutations of certain charged and hydrophobic residues in TP outside T3, and (iv) four cysteines in the spacer and RT ( Fig. 1A and B) . A number of mutations in the T3 and RT1 motifs of HP were recently assayed for their Hε RNA binding activity using an in vitro RNA binding assay in which purified HP was incubated with an in vitro-transcribed Hε RNA (26, 28, 47) , and many were found to be defective in HP-Hε binding (48) . Four RT1 mutants (V365A/D366A, N371A/T372A, A373G/E374A, and R386A/G387A), all competent in Hε binding in vitro but differing in their pgRNA packaging activities (see Fig. 8A for a summary), were selected here for further analysis to determine their Hε binding in vivo and protein priming activities. Three T3 mutants, K153A/A154G, G155A/ I156A, and K159A/R160A, which retained ca. 20%, 10%, and Ͻ5% of Hε binding activity, respectively, in vitro compared to WT HP and varying pgRNA packaging activity (see Fig. 8A ), were also analyzed. Additional single-residue substitution mutants in TP outside T3 (W74A, R105A, Y147A, and Y173A), in the spacer (C312A, C323A, and C327A), and in RT (C341A) were selected because they are defective in viral RNA packaging or DNA synthesis, but their Hε binding or protein priming activities were not defined (see Fig. 8A ) (40) (41) (42) .
The mutant HP constructs were cotransfected into HEK293T cells with a construct expressing Hε and purified as an HP-Hε complex (Fig. 1C, lanes 3 to 8, 10 , 13 to 16, and 19 to 22) (26) . In parallel, WT HP was also purified with or without Hε (Fig. 1C, lanes 1, 2, 9 , 11, 12, 17, and 18). Western blot analysis of WT and mutant HP proteins showed that the HP mutants were expressed at least as well as WT HP, and they all migrated at ca. 90 kDa (Fig. 1C) .
In vivo H binding activity of HP substitution mutants. To assess the ability of the HP mutants to bind to Hε in vivo, RNAs bound to purified HP proteins were extracted and detected by Northern blotting (26) . Of the T3 mutants tested, the G155A/ I156A and K159A/R160A mutants showed reduced (by ca. 70%) but readily detectable HP-Hε binding in vivo ( Fig. 2A , lanes 13 and 14, and see Fig. 8A ). All other T3 and RT1 motif mutants tested showed WT-level Hε binding activity ( Fig. 2A, lanes 12 and 15 to  18 ). Of the single-residue substitution mutants outside the T3 motif, three (R105A, Y147A, and Y173A) bound Hε at near-WT levels, and the remaining one (W74A) showed a modest (by ca. 40%) decrease in Hε binding (Fig. 2B , lanes 9 to 12, and see Fig.  8A ). All four cysteine mutants, C312A, C323A, C327A, and C341A, were severely defective in Hε binding (Fig. 2B , lanes 21 to 24, and see Fig. 8A ).
Protein priming activity of HP substitution mutants. Purified HP proteins, with or without bound Hε, were tested for their ability to carry out protein priming by using a recently developed in vitro protein priming assay (26) . Two mutants in the T3 motif, G155A/I156A and K159A/R160A, and two in the RT1 motif, V365A/D366A and R386A/G387A, were severely defective (deceased by ca. 90% to undetectable) in protein priming (Fig. 3A , lanes 4, 5, 6, and 9, and see Fig. 8A ). The remaining T3 mutant, K153A/A154G, showed WT-level priming activity (Fig. 3A, lane 3 , and see Fig. 8A ). The remaining two RT1 motif mutants, N371A/ T372A and A373G/E374A, showed modestly reduced (by ca. 70% and 50%, respectively) protein priming activity (Fig. 3A, lanes 7  and 8, and see Fig. 8A ). All the other HP mutants, with substitutions of the charged or hydrophobic residues in TP (outside T3) or the conserved cysteines in the spacer and RT for alanines, were completely defective in protein priming (Fig. 3A , lanes 12 to 15 and 17 to 20, and see Fig. 8A ).
We recently discovered a novel, template-independent but protein-primed, terminal transferase activity of HP, which is activated when Mn 2ϩ instead of Mg 2ϩ is used as the metal ion cofactor (28) . The synthesis of long stretches of DNA by this transferase activity depends on the RT active site and Y63 in TP as the primer, similar to Hε-templated viral DNA synthesis. The novel transferase activity of HP thus provides a system to dissect requirements of protein-primed DNA synthesis, such as primer positioning and catalysis per se, that are independent of the requirements for an Hε interaction. Therefore, we determined the transferase activities of the various HP mutants in the presence of Mn 2ϩ instead of Mg 2ϩ (Fig. 3B) . As we reported recently (28), the protein priming signal with Mn 2ϩ (i.e., transferase activity) in the presence or absence of Hε (Fig. 3B, lanes 1, 2, 10, 11 and 16 ) was stronger than that with Mg 2ϩ . This was probably due to the incorporation of multiple radiolabeled dGMP residues into the DNA strand that is attached to each HP molecule and also because more HP molecules were active in the transferase activity than in the Hε-dependent priming with Mg 2ϩ (28) . The relative priming activities with Mn 2ϩ of most HP mutants, compared to WT HP, were similar to those with Mg 2ϩ (Fig. 3B , lanes 3 to 9, 12, 13 15, and 17 to 20, and see Fig. 8A ). However, the Y147A mutant clearly had a protein-primed transferase activity with Mn 2ϩ that was similar to that of WT HP (Fig. 3B, lane 14, and see Fig. 8A ). This stood in sharp contrast to its severe defect in Hε-dependent protein priming with Mg 2ϩ (Fig. 3A , lane 14 and see Fig. 8A ). Mapping of HP domain boundaries for H binding, protein priming, and pgRNA packaging. To define the boundaries of the TP, RT, and RNase H domains required for HP functions in Hε binding, protein priming, and pgRNA packaging, we created Nterminal, internal (within the spacer), and C-terminal HP truncations (Fig. 4A ). All truncation mutants contained an internal deletion in the spacer region from positions 200 to 299 except for HP(1-175, 300 -775), which had a deletion from positions 176 to 299. The mutants were all expressed at least as well as WT HP (Fig.  4B) . When the truncation mutants were tested for their ability to bind Hε in vivo, all the mutants had WT-like Hε binding activity except for HP(1-199, 300 -661), which showed ca. 30% of WT activity, and HP(1-175, 300 -775), which strikingly lost all Hε binding activity (Fig. 5 ). When these same mutants were tested for their ability to carry out protein priming in the presence of Mg 2ϩ , only one mutant, HP(1-199, 300 -775), showed priming activity that was similar to that of WT HP (Fig. 6A, lane 5) . All the other truncation mutants were completely defective in Hε-dependent protein priming (Fig. 6A) . When the mutants were tested for their ability to carry out protein priming in the presence of Mn 2ϩ (i.e., Hε-independent transferase activity), HP(1-199, 300 -775) again had WT-like priming activity (Fig. 6B, lane 5) . HP(1-199, 300 -718) showed a low level (ca. 10% of the WT level) of priming activity (Fig. 6B, lanes 6 and 13, and see Fig. 8A ), and very weak priming signals (Ͻ5% of the WT level) were detectable with HP(20 -199, 300 -775), HP(40 -199, 300 -775), and HP(1-175, 300 -775) (Fig. 6B, lanes 9 to 11, and see Fig. 8A ). No priming signal could be detected with HP(1-199, 300 -661) (Fig. 6B,  lane 14) .
We also measured the ability of the truncated HP constructs to support pgRNA packaging using the trans-complementation RNA packaging assay. We found that all the truncation mutants, including the minimal C-terminal truncation mutant HP(1-175, 300 -775), were completely defective in pgRNA packaging (Fig. 7,  lanes 3 to 8) . Capsid assembly or HP expression was not impaired by the HP truncations (Fig. 7) . The T3 G155A/I156A mutant was 1 and 10; B, lanes 1, 7, 13, and 19) or HP or HP mutants coexpressed with Hε (A, lanes 2 to 9 and 11 to 18; B, lanes 2 to 6, 8 to 12, 14 to 18, and 20 to 24) were purified as outlined in Materials and Methods. RNAs were extracted from cytoplasmic lysates (A, lanes 1 to 10; B, lanes 1 to 6 and 13 to 18) or from the immunoaffinity-purified HP pellets (A, lanes 11 to 20; B, lanes 7 to 12 and 19 to 24) and were resolved on a urea-6% PAGE gel. A riboprobe specific for Hε was then used to detect lysate or bound Hε. Hε(II) represents the Hε-containing RNA produced from the transfected plasmid that is polyadenylated by using the strong bovine growth hormone poly(A) site ca. 220 nucleotides downstream from the weak HBV poly(A) site, which is used to produce the shorter Hε-containing RNA, designated Hε(I) (26) . Hε* denotes the Hε-containing RNA expressed as part of the much longer mRNA that encodes the WT or mutant HP proteins used in panel B. The HP expression plasmids used in panel B are different from those used in panel A and contain a 3= copy of Hε downstream of the HP coding sequence. This RNA also showed binding to HP (B, lanes 7 and 19). also included in the pgRNA packaging assay and was found to be as active as WT HP (Fig. 7, lane 9) , as we reported recently (48) .
DISCUSSION
Using our recently developed in vivo Hε RNA binding and Hε-dependent and -independent in vitro protein priming assays, we analyzed specific residues, motifs, and domain boundaries of HP that are important for HP-Hε binding and protein priming and further compared their roles in these processes to their role in pgRNA packaging (Fig. 8 ). Our results demonstrate that specific residues in both the TP and RT domains, including those within the T3 and RT1 motifs and elsewhere, are critical for Hε binding, protein priming, and pgRNA packaging. We have also found that almost the entire TP and RT domains and most of the RNase H domain were required for protein priming. Furthermore, pgRNA packaging required even more sequences from the RNase H domain than did protein priming. In contrast, only portions of TP and RT were needed for in vivo Hε binding.
Comparison of HP sequence requirements for Hε binding, protein priming, and pgRNA packaging allows five distinct groups of HP mutants tested here to be classified (Fig. 8A) : competent for all the HP activities tested (K153A/A154G at the N-terminal boundary of the T3 motif and N371A/T372A and A373G/E374A within the RT1 motif) (group 1), competent for Hε binding and pgRNA packaging but defective for protein priming (W74A, Y147A, and G155A/I156A in T3, and V365A/D366A in RT1) (group 2), competent for Hε binding and protein priming but defective for pgRNA packaging [HP(1-199, 300-775)] (group 3), competent for Hε binding but defective in pgRNA packaging and protein priming [R105A and Y173A in T3, R386A/G387A in RT1, HP , HP , HP(1-199, 300-718), and HP(1-199, 300-661)] (group 4), and defective in Hε binding, pgRNA packaging, and protein priming [K159A/R160A in T3, all four cysteine mutants in the spacer and RT, and HP(1-175, 300-775)] (group 5). Thus, our results clearly show that both protein priming and pgRNA packaging require additional HP sequences beyond those for Hε binding and furthermore that there are distinct HP requirements for pgRNA packaging and protein priming that can be genetically separated.
Our recent studies identified multiple T3 motif residues as important for Hε binding using the in vitro RNA binding assay (48) . We found here that two T3 mutants (K159A/R160A and, to a lesser degree, G155A/I156A) also showed reduced Hε binding in vivo. This confirms an important role of T3 in Hε binding, although the extent of the reduction was not as great as that found in the in vitro RNA binding assay. The four cysteines targeted here are conserved in the mammalian (but not the avian) hepadnaviruses and are known to be critical for pgRNA packaging (42) . The requirement of these residues for Hε binding provides an explanation for their role in pgRNA packaging observed previously and in protein priming found here. The domain truncation mutant in group 5 [HP(1-175, 300-775)] further suggests that the 24 amino 1 to 7) or from the immunoaffinity-purified HP pellets (lanes 8 to 14) and were resolved on a urea-6% PAGE gel. A riboprobe specific for Hε was then used to detect lysate or bound Hε. Hε(II) represents the Hε-containing RNA produced from the transfected plasmid that is polyadenylated by using the strong bovine growth hormone poly(A) site ca. 220 nucleotides downstream from the weak HBV poly(A) site, which is used to produce the shorter Hε-containing RNA, designated Hε(I) (26) . acid residues at the junction between TP and the spacer (positions 176 to 299) may also be critical for Hε binding. Thus, T3, the C-terminal region of TP, the conserved cysteines in the spacer and RT, and the RT1 motif in RT (48) are all required for Hε binding. Whether any of these sequences are involved directly in RNA binding or play a more indirect role (e.g., affecting the folding of local regions involved in Hε binding) remains to be determined.
We have identified a large number of HP mutants (group 4) distributed in TP, RT, and the RNase H domain that were defective in both protein priming and RNA packaging while remaining competent in Hε binding. This result supports the notion that both of these processes share similar requirements post-RNA binding, as also suggested by our previous observation that the Hε RNA requirements for pgRNA packaging and protein priming are similar (26) . How the sequences involved facilitate both of these HP functions beyond RNA binding remains to be elucidated. One possibility is that they may help establish an HP conformation, induced upon Hε binding, that is required for activation of the HP enzymatic activity as well as its RNA packaging function. Indeed, DP interaction with its cognate Dε RNA has been shown to induce DP conformational changes required for protein priming (23, 24) . On the other hand, the identification of the group 2 mutants defective in protein priming but competent for pgRNA packaging and the group 3 mutant competent for protein priming but defective for pgRNA packaging, with both groups being competent in Hε binding, clearly indicates that there are also distinct requirements for these two related processes, which are both triggered by HP-Hε binding. Similarly, DP mutants defective in pgRNA packaging but competent in protein priming have also been reported (49) . Previous studies showed that HP mutants truncated at position 744 (20) or position 729 (50) were defective in pgRNA packaging. Our analysis here has extended the C-terminal boundary of HP required for pgRNA packaging to beyond residue 775. The limited spacer (positions 200 to 299) deletion did not affect pgRNA packaging (S. A. Jones and J. Hu, unpublished results), in agreement with a previous report (20) . One interpretation for the phenotype of the HP(1-199, 300-775) mutant is that the RNase H sequences C terminal to residue 775 are specifically required for pgRNA packaging but not for protein priming, e.g., via an interaction with the viral capsid protein during nucleocapsid assembly. The sequences involved in the group 2 mutants, especially the TP sequences (W74, Y147, and G155/I156 in T3), may play a role in positioning Y63 in the RT active site to allow priming. The defect of W74A and Y147A mutants in protein priming could also ex- Ϫ , an HBV replication construct encoding pgRNA and all viral proteins except HP, and the indicated HP construct or the pCDNA3 vector control. Viral RNA packaged into nucleocapsids was detected by resolving the capsids on an agarose gel, after which they were transferred onto a nitrocellulose membrane. A riboprobe specific for Hε was used to detect packaged RNA (top), while the same membrane was probed subsequently with an anti-HBV core antibody (middle). Cell lysates were also resolved by SDS-PAGE, and HP expression was detected by Western blotting using the anti-Flag antibody (bottom). The positions of HP and the protein molecular mass markers are indicated. mediate pgRNA packaging (this and previous studies), and to carry out protein priming (this study) are summarized. ** indicates that the RNA packaging results designated "positive" or "negative" were obtained in previous analyses (40) (41) (42) 48) . All results reported here represent the averages of at least three independent experiments. Ϫ, Ͻ10% of WT activity; ϩ, 10 to 30% of WT activity; ϩϩ, 30 to 70% of WT activity; ϩϩϩ, Ͼ70% of WT activity; ***, differential priming activity of the Y147A mutant with Mn plain the previously reported observation that these mutants could package pgRNA but could not make viral DNA (41) . The RT1 V365/D366 sequences could also be involved in primer positioning or perhaps more directly in catalysis.
Our mapping results for HP domain boundaries involved in Hε binding in vivo are fully consistent with our previous results obtained using an in vitro RNA binding assay with bacterially expressed and chaperone-reconstituted HP (13) . Both studies showed that the N-terminal portion of TP, the C-terminal portion of RT, and the entire RNase H domain are dispensable for Hε binding (Fig. 8C) . This is similar to the requirement of DP in Dε binding (12, 44) . On the other hand, the HP domain requirements for protein priming are dramatically different from those for DP. Almost the entire TP and RT domains and the majority of the RNase H domain were required for protein priming in the presence of either Mg 2ϩ (Hε dependent) or Mn 2ϩ (Hε independent). The sequences at the junction between TP and the spacer (positions 176 to 199) were found to be critical for the Hε-independent transferase activity both in this study and in a previous report (37) , in addition to its essential role in Hε binding, as discussed above. In contrast, DP can carry out protein priming efficiently without the RNase H domain entirely and with significant truncations at the N terminus of TP and the C terminus of RT (43, 51) . Also, R105 in HP is critical for both protein priming (this study) and pgRNA packaging (40) . In contrast, the equivalent DP residue, R128, is not required for DP protein priming or pgRNA packaging (52) . These discordances between HP and DP highlight important differences in the sequence requirements for protein priming and RNA packaging between these two related proteins and suggest caution in extrapolating observations made with DP to HP.
The strong, Mn 2ϩ -dependent, and template-independent protein priming (i.e., transferase) activity of the Y147A mutant, in contrast to its severe defect in Mg 2ϩ -dependent and Hε-templated protein priming, indicates that it is possible to separate genetically these activities (Fig. 3 and 8A ). This may also be true, to a lesser extent, for the W74A and R386A/G387A mutations. These mutations also had little effect on HP-Hε binding. Assuming that the Y63 primer is positioned into the RT active site similarly for catalysis of the covalent phosphotyrosyl linkage between the nucleotide and Y63 in both priming reactions, the deleterious effect of these mutations preferentially on Hε-dependent protein priming versus Hε-independent transferase activity may suggest that they are specifically involved in properly aligning the Hε RNA template relative to the RT active site and/or the Y63 primer. On the other hand, the HP requirements for both priming reactions are quite similar, including the need for the YMDD RT active site and the Y63 primer, the domain boundary requirements, and the fact that most HP mutations tested here affected the two priming reactions similarly. The domain requirements of protein priming using HP expressed in insect cells are also very similar to what we have defined here (37) . Although the protein priming activity of the insect cell-derived HP was conducted with Mg 2ϩ , it was Hε independent, and its nucleotide selectivity also mimicked the transferase activity that we detected using human cell-derived HP and Mn 2ϩ . Thus, the transferase activity of HP may also manifest itself in the presence of Mg 2ϩ when it is expressed in heterologous host cells.
All current direct-acting antiviral drugs used to treat HBV infections are nucleos(t)ide analogs that inhibit the DNA polymerase activity of HP (2, 53, 54) . Furthermore, with few exceptions, these drugs inhibit the elongation stage of viral DNA synthesis, with no effect on protein priming (2, 47) . Thus, the protein priming function as well as the Hε binding and pgRNA packaging functions of HP represent un-or underexploited targets for antiviral development against HBV. Our analysis of the HP requirements for these essential and related viral processes has revealed additional HP targets for developing novel antivirals to inhibit HP functions beyond its DNA polymerase activity.
